Secondly, the present study estimated the lifetime effect of plasma ICAM-4 in the risks of ischemic stroke and its subtypes, so the results should not be directly extrapolated to assess the effect of any potential clinical intervention targeting ICAM-4. The gene discussed is ICAM4; the disease is ischemic stroke.